BVF Inc. IL Reduces Stock Holdings in Axsome Therapeutics, Inc. $AXSM

BVF Inc. IL decreased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 90.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,757 shares of the company’s stock after selling 441,000 shares during the period. BVF Inc. IL’s holdings in Axsome Therapeutics were worth $8,357,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of AXSM. Kemnay Advisory Services Inc. purchased a new position in Axsome Therapeutics in the fourth quarter valued at approximately $31,000. Optiver Holding B.V. lifted its stake in Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after purchasing an additional 130 shares during the last quarter. Advisory Services Network LLC purchased a new position in Axsome Therapeutics in the third quarter valued at approximately $40,000. GAMMA Investing LLC lifted its stake in Axsome Therapeutics by 65.4% in the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after purchasing an additional 106 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Axsome Therapeutics by 602.6% in the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock valued at $50,000 after purchasing an additional 235 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling

In related news, Director Mark Coleman sold 643 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total value of $160,107.00. Following the sale, the director owned 30,389 shares in the company, valued at approximately $7,566,861. This trade represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Nick Pizzie sold 33,000 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total value of $7,922,970.00. Following the completion of the sale, the chief financial officer owned 42,867 shares in the company, valued at $10,291,938.03. This trade represents a 43.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 113,686 shares of company stock valued at $26,666,006 in the last ninety days. 20.60% of the stock is owned by insiders.

Axsome Therapeutics Trading Up 0.1%

Shares of AXSM stock opened at $252.16 on Thursday. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. Axsome Therapeutics, Inc. has a 52-week low of $96.09 and a 52-week high of $257.92. The company has a market capitalization of $12.98 billion, a PE ratio of -67.60 and a beta of 0.61. The business’s fifty day moving average is $215.95 and its 200 day moving average is $184.31.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business had revenue of $191.20 million during the quarter, compared to analysts’ expectations of $191.10 million. The company’s revenue was up 57.4% compared to the same quarter last year. On average, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on AXSM shares. Needham & Company LLC increased their target price on Axsome Therapeutics from $225.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Piper Sandler restated an “overweight” rating and set a $258.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Wolfe Research started coverage on Axsome Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $230.00 target price on the stock. Royal Bank Of Canada increased their target price on Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Finally, Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Axsome Therapeutics in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $258.95.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.